Access cutting-edge melanoma treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.
Access melanoma specialists in Chicago at no cost
This study follows strict safety protocols and ethical guidelines
All study-related melanoma treatment provided free
This is a Phase 3, multicenter, open-label, randomized, parallel group, treatment study to assess the efficacy and safety of lifileucel in combination with pembrolizumab compared with pembrolizumab alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who subsequently have a blinded independent central review- verified confirmed progressive disease (PD) will be offered lifileucel monotherapy in an optional crossove
Sponsor: Iovance Biotherapeutics, Inc.
Check if you qualify for this melanoma clinical trial in Chicago, IL
If you're searching for melanoma treatment options in Chicago, IL, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced melanoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.